Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy ...

By Stephen Beech Men with advanced prostate cancer have been offered fresh hope thanks to a "promising" new drug combination.

This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...